PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2015
CASE
AUTH/2792/9/15 GlaxoSmithKline

AUTH/2792/9/15: Anonymous v GlaxoSmithKline (SUMMIT study press release) β€” No breach

Anonymous complaint alleged GSK’s SUMMIT study press release was misleading (use of β€œsurvival”, 12.2% lower risk of dying) and omitted the black…

2015
CASE
AUTH/2755/5/15 A. Menarini Farmaceutica Internazionale S.r.l.

A Menarini misleading cost messaging and email permission failures in payer promotion for Adenuric (AUTH/2755/5/15)

A payer-targeted email highlighted a 29% allopurinol price rise and implied Adenuric could help manage long-term costs. PMCPA found the material misleading…

2014
CASE
AUTH/2739/11/14 Daiichi-Sankyo UK

AUTH/2739/11/14: Pfizer/Bristol-Myers Squibb v Daiichi Sankyo – advance budgetary notification and pre-licence promotion risk (edoxaban)

Daiichi Sankyo’s publicly accessible forum website synopsis for an β€œadvance budgetary notification” workshop about an unlicensed anticoagulant (edoxaban) was ruled insufficiently targeted,…

2014
CASE
AUTH/2727/8/14 Pierre Fabre

Pierre Fabre found in breach over β€˜under-dosing’ Navelbine Oral letter to oncology pharmacists (AUTH/2727/8/14)

A β€˜safety’ letter about Navelbine Oral dosing was ruled promotional. Missing prescribing info and AE reporting, an unqualified indication, and misleading/unsupported efficacy-survival…

2014
CASE
AUTH/2713/5/14 Eli Lilly ⭐ Case of the Week

AUTH/2713/5/14: Chief Pharmacist v Eli Lilly β€” Strattera nurse speaker engagement (No breach)

An NHS chief pharmacist alleged a Strattera nurse speaker contract looked like inducement/seeding research and queried disclosure. PMCPA found misunderstanding from wording…

2013
CASE
AUTH/2665/11/13 Genzyme

AUTH/2665/11/13: Genzyme (Sanofi) – clinical trial disclosure delays for Mozobil; no breach for Renvela (timing pre-Code)

Public complaint about clinical trial transparency data. Panel found delayed disclosure for one UK-involved Mozobil trial (breach Clauses 9.1, 21.3). Renvela issues…

2008
CASE
AUTH/2084/1/08 Novartis Pharmaceuticals UK

AUTH/2084/1/08: Anonymous v Novartis β€” hospitality at educational meeting (no breach)

Anonymous complaint alleged excessive hospitality and poor rep conduct at a Novartis-sponsored restaurant meeting. Panel said costs/drinks were at the outer limits…

2015
CASE
AUTH/2815/12/15 Piramal Healthcare UK

AUTH/2815/12/15: AbbVie v Piramal β€” Sevoflurane β€œdrop test” leaflet treated as promotional; missing cost, AE statement and date

A sevoflurane packaging β€œdrop test” leaflet was ruled promotional. It omitted the medicine’s cost, the mandatory adverse event reporting statement and the…

2016
CASE
AUTH/2853/6/16 GlaxoSmithKline

AUTH/2853/6/16: Anonymous v GlaxoSmithKline (Telegraph Online malaria vaccine corporate ad) – No breach

Anonymous complaint alleged GSK promoted an unlicensed malaria vaccine to the public via a Telegraph Online ad. PMCPA ruled the 30-second video…

2016
CASE
AUTH/2919/12/16 Merck Sharp & Dohme ⭐ Case of the Week

AUTH/2919/12/16: Anonymous (non-contactable) v Merck Sharp & Dohme β€” no breach (representative conduct allegation)

Anonymous GP alleged an MSD representative brought her daughter to meetings. MSD found no record of any complaint. Panel said allegation not…

2016
CASE
AUTH/2864/8/16 Boehringer Ingelheim

AUTH/2864/8/16: Anonymous (non-contactable) v Boehringer Ingelheim – consultant/training company engagement (No breach)

Anonymous complaint alleged industry-funded audits/training via a nurse-owned consultancy influenced prescribing in a CCG. Panel found no evidence to support inducement allegations;…

2016
CASE
AUTH/2918/12/16 GlaxoSmithKline

AUTH/2918/12/16: Ex-employee v GlaxoSmithKline (Relvar Ellipta cost calculator) – No breach

An ex-employee found a Relvar Ellipta cost calculator via search engines that appeared to lack PI, AE statement and black triangle. Panel…

2012
CASE
Novo Nordisk

Sanofi v Novo Nordisk: Tresiba leavepiece claims (75% less variability; 142 fewer nocturnal hypoglycaemic events) ruled misleading

Novo Nordisk’s Tresiba leavepiece overstated clamp-study variability data and visually exaggerated a nocturnal hypoglycaemia comparison. PMCPA ruled breaches of Clauses 7.2, 7.3,…

2017
CASE
AUTH/2949/3/17 A Menarini ⭐ Case of the Week

A. Menarini: Broken website links and missing Yellow Card reference on products page (AUTH/2949/3/17)

A hospital doctor couldn’t find working adverse event reporting or a Yellow Card link on Menarini’s website. Panel ruled breaches for missing…

2018
CASE
AUTH/3022/2/18 Servier Laboratories

AUTH/3022/2/18 & AUTH/3023/2/18: Health professionals v Servier (alleged Windsor Castle meeting sponsorship) – No breach

Two HCPs alleged Servier sponsored a learned society weekend meeting at Windsor Castle. Servier showed it declined sponsorship due to venue risk…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training